Corteva Earnings Call Transcripts
Fiscal Year 2026
-
Strong Q1 growth and robust global demand set a positive tone ahead of the planned Q4 separation into focused seed and crop protection entities. Strategic investments in gene editing, hybrid wheat, and licensing are expected to drive significant long-term growth, while both new companies will maintain strong balance sheets and pursue innovation-led strategies.
-
Q1 2026 saw 21% EBITDA growth and margin expansion, driven by strong Seed and Crop Protection performance. Full-year guidance is reaffirmed, with continued organic growth, cost productivity, and progress on the planned separation into two companies.
-
The meeting highlighted strong financial growth, major R&D investment, and a planned separation into two companies with new leadership. All director nominees and proposals were approved, and the company emphasized innovation and a shift toward sustainable solutions.
-
2025 saw strong financial and operational performance, with robust ammonia and nitrogen markets supported by efficient logistics and growing demand. Strategic investments in low-carbon ammonia, modular construction, and supply chain resilience position the business for continued growth amid policy and market uncertainties.
Fiscal Year 2025
-
Delivered strong 2025 results with double-digit EBITDA growth, margin expansion, and robust free cash flow. 2026 guidance calls for 7% EBITDA growth, margin gains, and accelerated royalty neutrality following a major Bayer agreement, despite ongoing pricing and tariff headwinds.
-
Strong Q3 and year-to-date results led to raised 2025 guidance, with double-digit EBITDA growth, margin expansion, and robust free cash flow. The planned separation into two public companies is on track, with both seed and crop protection segments showing innovation and market leadership.
-
A separation into two companies—crop protection and seed—was announced to unlock long-term value, with both entities retaining strong balance sheets and tailored growth strategies. The split is expected to be low in complexity, with manageable costs and no new liabilities anticipated.
-
Q2 and H1 2025 saw strong sales, margin expansion, and cost improvements, leading to raised full-year guidance for EBITDA, EPS, and free cash flow. Seed and crop protection segments both delivered double-digit EBITDA growth, with robust share gains and new product momentum.
-
Strategy and execution improvements have driven strong financial performance and optimism, with technology and product innovation setting up for significant growth. Tariff impacts are manageable, cost efficiencies are on track, and new products like hybrid wheat and short-stature corn are expected to launch in 2027. Capital allocation remains balanced, supporting both shareholder returns and R&D.
-
Q1 delivered 15% EBITDA growth, driven by new products, cost improvements, and strong volumes, with full-year guidance up 10%. Innovation in gene editing, hybrid wheat, and biologicals underpins a robust pipeline, while tariff and FX headwinds are being actively managed.
-
Q1 2025 saw 15% EBITDA growth and nearly 400 bps margin expansion, driven by operational excellence and growth in biologicals, new crop protection products, and seed out-licensing. Full-year guidance is reaffirmed, with manageable tariff impacts and strong cost savings supporting robust outlook.
-
Entering 2025 with strong global demand, tight crop inventories, and healthy pricing, the company projects double-digit EBITDA and EPS growth, driven by proprietary products, out-licensing, and biologicals. Strategic M&A, cost discipline, and innovation in gene editing and biofuels underpin long-term growth.
Fiscal Year 2024
-
Delivered record Q4 and full-year results with 20% EBITDA margin, strong seed and crop protection performance, and $1.7B free cash flow. 2025 guidance targets 10% EBITDA growth, margin expansion, and $1B in share repurchases, despite FX headwinds and flat crop protection market.
-
Corteva targets $1B in incremental revenue by 2027 from out-licensing, biologicals, and new CP products, with major growth also expected from gene editing, biofuels, and hybrid wheat. The company projects a 9% EBITDA CAGR and nearly 400 bps margin expansion by 2027.
-
Third quarter results met expectations, with strong execution in cost savings and margin growth in crop protection, while seed performance remained robust. 2024 guidance was lowered due to Latin America headwinds, but double-digit EBITDA growth and margin expansion are expected in 2025.
-
Solid H1 2024 results were driven by seed business growth and cost discipline, while crop protection volumes rebounded. Guidance was lowered due to Argentina's corn stunt and weather, but strong Q4 and 2025 prospects are expected, with deflationary tailwinds and innovation in gene editing and biofuels supporting future growth.
-
Q2 2024 saw margin expansion and strong Seed performance, while crop protection volumes rebounded but pricing remained pressured. Full-year guidance was lowered slightly due to market and weather impacts, but cost tailwinds and robust free cash flow are expected.
-
Celebrating five years as a public company, the firm highlighted strong seed business momentum, robust cost controls, and ongoing innovation. 2024 guidance remains steady despite weather-related shifts, with a focus on long-term growth, margin expansion, and upcoming strategic updates at the November investor day.